1. Home
  2. BIVI vs XTKG Comparison

BIVI vs XTKG Comparison

Compare BIVI & XTKG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIVI
  • XTKG
  • Stock Information
  • Founded
  • BIVI 2013
  • XTKG 1997
  • Country
  • BIVI United States
  • XTKG Singapore
  • Employees
  • BIVI N/A
  • XTKG N/A
  • Industry
  • BIVI Biotechnology: Pharmaceutical Preparations
  • XTKG
  • Sector
  • BIVI Health Care
  • XTKG
  • Exchange
  • BIVI Nasdaq
  • XTKG NYSE
  • Market Cap
  • BIVI 45.1M
  • XTKG 53.6M
  • IPO Year
  • BIVI N/A
  • XTKG 2019
  • Fundamental
  • Price
  • BIVI $3.11
  • XTKG $0.11
  • Analyst Decision
  • BIVI Strong Buy
  • XTKG
  • Analyst Count
  • BIVI 2
  • XTKG 0
  • Target Price
  • BIVI $40.00
  • XTKG N/A
  • AVG Volume (30 Days)
  • BIVI 3.3M
  • XTKG 2.7M
  • Earning Date
  • BIVI 11-13-2024
  • XTKG 11-29-2024
  • Dividend Yield
  • BIVI N/A
  • XTKG N/A
  • EPS Growth
  • BIVI N/A
  • XTKG N/A
  • EPS
  • BIVI N/A
  • XTKG N/A
  • Revenue
  • BIVI N/A
  • XTKG $16,824,823.00
  • Revenue This Year
  • BIVI N/A
  • XTKG N/A
  • Revenue Next Year
  • BIVI N/A
  • XTKG N/A
  • P/E Ratio
  • BIVI N/A
  • XTKG N/A
  • Revenue Growth
  • BIVI N/A
  • XTKG 60.50
  • 52 Week Low
  • BIVI $1.04
  • XTKG $0.08
  • 52 Week High
  • BIVI $56.54
  • XTKG $1.64
  • Technical
  • Relative Strength Index (RSI)
  • BIVI 56.34
  • XTKG 39.25
  • Support Level
  • BIVI $2.87
  • XTKG $0.10
  • Resistance Level
  • BIVI $3.85
  • XTKG $0.15
  • Average True Range (ATR)
  • BIVI 0.39
  • XTKG 0.02
  • MACD
  • BIVI 0.01
  • XTKG 0.00
  • Stochastic Oscillator
  • BIVI 51.32
  • XTKG 39.51

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

About XTKG X3 HOLDINGS CO LTD

X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries that operates across four business segments: digital technologies, renewable energy, Cryptomining Operations, and agriculture technologies.

Share on Social Networks: